{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:45:56Z","timestamp":1776350756641,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hebei Natural Science Foundation Project","award":["No. H2024423028"],"award-info":[{"award-number":["No. H2024423028"]}]},{"name":"Hebei Natural Science Foundation Project","award":["H2023423001"],"award-info":[{"award-number":["H2023423001"]}]},{"name":"Research Plan Project of Hebei Provincial Administration of Traditional Chinese Medicine","award":["No. 2023035"],"award-info":[{"award-number":["No. 2023035"]}]},{"name":"The Science and Technology Project of the State Administration of Traditional Chinese Medicine","award":["GZY-KJS-2023-025"],"award-info":[{"award-number":["GZY-KJS-2023-025"]}]},{"name":"Hebei Province Central Government Guided Local Science and Technology Special Project","award":["No. 246Z7708G"],"award-info":[{"award-number":["No. 246Z7708G"]}]},{"name":"Hebei Provincial Science and Technology Plan Funding Project","award":["246W7701D"],"award-info":[{"award-number":["246W7701D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-025-01596-4","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:42:14Z","timestamp":1736296934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The immunohistochemical combination of low SGLT2 expression and high PRDX4 expression independently predicts shortened survival in patients undergoing surgical resection for hepatoblastoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Yao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Shioya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu Anh","family":"Dung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohsuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"1596_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1093526619875228","volume":"23","author":"S Ranganathan","year":"2020","unstructured":"Ranganathan S, Lopez-Terrada D, Alaggio R. Hepatoblastoma and Pediatric Hepatocellular Carcinoma: an update. Pediatr Dev Pathol. 2020;23:79\u201395. https:\/\/doi.org\/10.1177\/1093526619875228.","journal-title":"Pediatr Dev Pathol"},{"key":"1596_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3971\/j.issn.1000-8578.2022.21.1476","volume":"49","author":"J Zhan","year":"2022","unstructured":"Zhan J, Wang Z. Progress and comment on Surgical Treatment of Hepatoblastoma in Children. Cancer Res Prev Treat. 2022;49:541\u20135. https:\/\/doi.org\/10.3971\/j.issn.1000-8578.2022.21.1476.","journal-title":"Cancer Res Prev Treat"},{"key":"1596_CR3","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.31193","volume":"142","author":"K Kaji","year":"2018","unstructured":"Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142:1712\u201322. https:\/\/doi.org\/10.1002\/ijc.31193.","journal-title":"Int J Cancer"},{"key":"1596_CR4","doi-asserted-by":"publisher","first-page":"e0274519","DOI":"10.1371\/journal.pone.0274519","volume":"17","author":"M Hendryx","year":"2022","unstructured":"Hendryx M, Dong Y, Ndeke JM, Luo J. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS ONE. 2022;17:e0274519. https:\/\/doi.org\/10.1371\/journal.pone.0274519.","journal-title":"PLoS ONE"},{"key":"1596_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.canlet.2021.07.035","volume":"519","author":"D Ren","year":"2021","unstructured":"Ren D, Sun Y, Zhang D, Li D, Liu Z, Jin X, Wu H. SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis. Cancer Lett. 2021;519:277\u201388. https:\/\/doi.org\/10.1016\/j.canlet.2021.07.035.","journal-title":"Cancer Lett"},{"key":"1596_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","volume":"6","author":"A Ali","year":"2023","unstructured":"Ali A, Mekhaeil B, Biziotis OD, Tsakiridis EE, Ahmadi E, Wu J, Wang S, Singh K, Menjolian G, Farrell T, Mesci A, Liu S, Berg T, Bramson JL, Steinberg GR, Tsakiridis T. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun Biol. 2023;6:919. https:\/\/doi.org\/10.1038\/s42003-023-05289-w.","journal-title":"Commun Biol"},{"key":"1596_CR7","doi-asserted-by":"publisher","first-page":"45024","DOI":"10.1038\/srep45024","volume":"7","author":"AM Blanco","year":"2017","unstructured":"Blanco AM, Bertucci JI, Ramesh N, Delgado MJ, Valenciano AI, Unniappan S. Ghrelin facilitates GLUT2-, SGLT1- and SGLT2-mediated Intestinal Glucose Transport in Goldfish (Carassius auratus). Sci Rep. 2017;7:45024. https:\/\/doi.org\/10.1038\/srep45024.","journal-title":"Sci Rep"},{"key":"1596_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1159\/000536060","volume":"102","author":"S Iwai","year":"2024","unstructured":"Iwai S, Motono N, Oyama T, Shioya A, Yamada S, Uramoto H. The clinical relevance of the expression of SGLT2 in Lung Adenocarcinoma. Oncology. 2024;102:710\u20139. https:\/\/doi.org\/10.1159\/000536060.","journal-title":"Oncology"},{"key":"1596_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40264-023-01373-6","volume":"47","author":"F Wang","year":"2024","unstructured":"Wang F, Hendryx M, Liu N, Bidulescu A, Mitra AK, Luo J. SGLT2 inhibitor use and risk of breast Cancer among adult women with type 2 diabetes. Drug Saf. 2024;47:125\u201333. https:\/\/doi.org\/10.1007\/s40264-023-01373-6.","journal-title":"Drug Saf"},{"key":"1596_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/jcdd10080322","volume":"10","author":"B Rolek","year":"2023","unstructured":"Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, G\u0105secka A. SGLT2 inhibitors vs. GLP-1 agonists to treat the heart, the kidneys and the brain. J Cardiovasc Dev Dis. 2023;10:322. https:\/\/doi.org\/10.3390\/jcdd10080322.","journal-title":"J Cardiovasc Dev Dis"},{"key":"1596_CR11","doi-asserted-by":"publisher","first-page":"1115413","DOI":"10.3389\/fmed.2023.1115413","volume":"10","author":"A Nishiyama","year":"2023","unstructured":"Nishiyama A, Kitada K. Possible renoprotective mechanisms of SGLT2 inhibitors. Front Med (Lausanne). 2023;10:1115413. https:\/\/doi.org\/10.3389\/fmed.2023.1115413.","journal-title":"Front Med (Lausanne)"},{"key":"1596_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.freeradbiomed.2015.01.025","volume":"83","author":"J Fujii","year":"2015","unstructured":"Fujii J, Ikeda Y, Kurahashi T, Homma T. Physiological and pathological views of peroxiredoxin 4. Free Radic Biol Med. 2015;83:373\u20139. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.01.025.","journal-title":"Free Radic Biol Med"},{"key":"1596_CR13","doi-asserted-by":"publisher","first-page":"153303381986431","DOI":"10.1177\/1533033819864313","volume":"18","author":"W Jia","year":"2019","unstructured":"Jia W, Chen P, Cheng Y. PRDX4 and its roles in various cancers. Technol Cancer Res Treat. 2019;18:1533033819864313. https:\/\/doi.org\/10.1177\/1533033819864313.","journal-title":"Technol Cancer Res Treat"},{"key":"1596_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12967-021-02792-8","volume":"19","author":"M Xu","year":"2021","unstructured":"Xu M, Xu J, Zhu D, Su R, Zhuang B, Xu R, Li L, Chen S, Ling Y. Expression and prognostic roles of PRDXs gene family in hepatocellular carcinoma. J Transl Med. 2021;19:126. https:\/\/doi.org\/10.1186\/s12967-021-02792-8.","journal-title":"J Transl Med"},{"key":"1596_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.prp.2018.03.026","volume":"214","author":"HX Li","year":"2018","unstructured":"Li HX, Sun XY, Yang SM, Wang Q, Wang ZY. Peroxiredoxin 1 promoted tumor metastasis and angiogenesis in colorectal cancer. Pathol Res Pract. 2018;214:655\u201360. https:\/\/doi.org\/10.1016\/j.prp.2018.03.026.","journal-title":"Pathol Res Pract"},{"key":"1596_CR16","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.3390\/ijms20184407","volume":"20","author":"T Ismail","year":"2019","unstructured":"Ismail T, Kim Y, Lee H, Lee DS, Lee HS. Interplay between mitochondrial peroxiredoxins and ROS in Cancer Development and Progression. Int J Mol Sci. 2019;20:4407. https:\/\/doi.org\/10.3390\/ijms20184407.","journal-title":"Int J Mol Sci"},{"key":"1596_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.018","volume":"163","author":"MH Park","year":"2016","unstructured":"Park MH, Jo M, Kim YR, Lee CK, Hong JT. Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases. Pharmacol Ther. 2016;163:1\u201323. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.03.018.","journal-title":"Pharmacol Ther"},{"key":"1596_CR18","doi-asserted-by":"publisher","first-page":"114896","DOI":"10.1016\/j.biopha.2023.114896","volume":"164","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang P, Hu W, Chen D. New insights into the roles of peroxiredoxins in cancer. Biomed Pharmacother. 2023;164:114896. https:\/\/doi.org\/10.1016\/j.biopha.2023.114896.","journal-title":"Biomed Pharmacother"},{"key":"1596_CR19","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1089\/ars.2012.4946","volume":"19","author":"A Nabeshima","year":"2013","unstructured":"Nabeshima A, Yamada S, Guo X, Tanimoto A, Wang KY, Shimajiri S, Kimura S, Tasaki T, Noguchi H, Kitada S, Watanabe T, Fujii J, Kohno K, Sasaguri Y. Peroxiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model. Antioxid Redox Signal. 2013;19:1983\u201398. https:\/\/doi.org\/10.1089\/ars.2012.4946.","journal-title":"Antioxid Redox Signal"},{"key":"1596_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/pin.12634","volume":"68","author":"S Yamada","year":"2018","unstructured":"Yamada S, Guo X. Peroxiredoxin 4 (PRDX4): its critical in vivo roles in animal models of metabolic syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease. Pathol Int. 2018;68:91\u2013101. https:\/\/doi.org\/10.1111\/pin.12634.","journal-title":"Pathol Int"},{"key":"1596_CR21","first-page":"2726","volume":"12","author":"J Zheng","year":"2020","unstructured":"Zheng J, Guo X, Shioya A, Yoshioka T, Matsumoto K, Hiraki T, Kusano H, Oyama T, Kurose N, Yamaguchi R, Uramoto H, Ieiri S, Okajima H, Kohno M, Yamada S. Peroxiredoxin 4 promotes embryonal hepatoblastoma cell migration but induces fetal cell differentiation. Am J Transl Res. 2020;12:2726\u201337.","journal-title":"Am J Transl Res"},{"key":"1596_CR22","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.3892\/ol.2020.11468","volume":"19","author":"SY Park","year":"2020","unstructured":"Park SY, Lee YJ, Park J, Kim TH, Hong SC, Jung EJ, Ju YT, Jeong CY, Park HJ, Ko GH, Song DH, Park M, Yoo J, Jeong SH. PRDX4 overexpression is associated with poor prognosis in gastric cancer. Oncol Lett. 2020;19:3522\u201330. https:\/\/doi.org\/10.3892\/ol.2020.11468.","journal-title":"Oncol Lett"},{"key":"1596_CR23","doi-asserted-by":"publisher","first-page":"8262730","DOI":"10.1155\/2020\/8262730","volume":"2020","author":"J Zheng","year":"2020","unstructured":"Zheng J, Guo X, Nakamura Y, Zhou X, Yamaguchi R, Zhang J, Ishigaki Y, Uramoto H, Yamada S. Overexpression of PRDX4 modulates Tumor Microenvironment and promotes urethane-Induced Lung Tumorigenesis. Oxid Med Cell Longev. 2020;2020:8262730. https:\/\/doi.org\/10.1155\/2020\/8262730.","journal-title":"Oxid Med Cell Longev"},{"key":"1596_CR24","doi-asserted-by":"publisher","first-page":"147201","DOI":"10.1016\/j.gene.2023.147201","volume":"859","author":"B Kocat\u00fcrk","year":"2023","unstructured":"Kocat\u00fcrk B. In silico analysis reveals PRDX4 as a prognostic and oncogenic marker in renal papillary cell carcinoma. Gene. 2023;859:147201. https:\/\/doi.org\/10.1016\/j.gene.2023.147201.","journal-title":"Gene"},{"key":"1596_CR25","doi-asserted-by":"publisher","first-page":"109825","DOI":"10.1016\/j.cellsig.2020.109825","volume":"77","author":"S Sukhanov","year":"2021","unstructured":"Sukhanov S, Higashi Y, Yoshida T, Mummidi S, Aroor AR, Jeffrey Russell J, Bender SB, DeMarco VG, Chandrasekar B. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1\u03b2 and IL-18 secretion. Cell Signal. 2021;77:109825. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109825.","journal-title":"Cell Signal"},{"issue":"7","key":"1596_CR26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jcjd.2019.01.005","volume":"43","author":"VK Pulakazhi Venu","year":"2019","unstructured":"Pulakazhi Venu VK, El-Daly M, Saifeddine M, Hirota SA, Ding H, Triggle CR, Hollenberg MD. Minimizing Hyperglycemia-Induced Vascular endothelial dysfunction by inhibiting endothelial sodium-glucose cotransporter 2 and attenuating oxidative stress: implications for treating individuals with type 2 diabetes. Can J Diabetes. 2019;43(7):510\u20134. https:\/\/doi.org\/10.1016\/j.jcjd.2019.01.005.","journal-title":"Can J Diabetes"},{"key":"1596_CR27","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Terrada D, Alaggio R, de D\u00e1vila MT, Czauderna P, Hiyama E, Katzenstein H, Leuschner I, Malogolowkin M, Meyers R, Ranganathan S, Tanaka Y, Tomlinson G, Fabr\u00e8 M, Zimmermann A, Finegold MJ, Children\u2019s Oncology Group Liver Tumor Committee. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2014;27:472\u2013491. https:\/\/doi.org\/10.1038\/modpathol.2013.80","DOI":"10.1038\/modpathol.2013.80"},{"key":"1596_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-77736-8_1","volume":"1063","author":"S Bose","year":"2018","unstructured":"Bose S, Le A. Glucose metabolism in Cancer. Adv Exp Med Biol. 2018;1063:3\u201312. https:\/\/doi.org\/10.1007\/978-3-319-77736-8_1.","journal-title":"Adv Exp Med Biol"},{"key":"1596_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152. https:\/\/doi.org\/10.1186\/1476-4598-12-152.","journal-title":"Mol Cancer"},{"key":"1596_CR30","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.4155\/fmc-2019-0052","volume":"11","author":"Y Meng","year":"2019","unstructured":"Meng Y, Xu X, Luan H, Li L, Dai W, Li Z, Bian J. The progress and development of GLUT1 inhibitors targeting cancer energy metabolism. Future Med Chem. 2019;11:2333\u201352. https:\/\/doi.org\/10.4155\/fmc-2019-0052.","journal-title":"Future Med Chem"},{"key":"1596_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4614-5915-6_1","volume":"772","author":"K Bensaad","year":"2014","unstructured":"Bensaad K, Harris AL. Hypoxia and metabolism in cancer. Adv Exp Med Biol. 2014;772:1\u201339. https:\/\/doi.org\/10.1007\/978-1-4614-5915-6_1.","journal-title":"Adv Exp Med Biol"},{"key":"1596_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/15384101.2021.1885236","volume":"20","author":"C Zhu","year":"2021","unstructured":"Zhu C, He X, Chen K, Huang Z, Yao A, Tian X, You Y, Zeng M. LncRNA NBR2 aggravates hepatoblastoma cell malignancy and promotes cell proliferation under glucose starvation through the miR-22\/TCF7 axis. Cell Cycle. 2021;20:575\u201390. https:\/\/doi.org\/10.1080\/15384101.2021.1885236.","journal-title":"Cell Cycle"},{"key":"1596_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jhbp.1391","volume":"31","author":"S Fujiyoshi","year":"2024","unstructured":"Fujiyoshi S, Honda S, Ara M, Kondo T, Kobayashi N, Taketomi A. SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma. J Hepatobiliary Pancreat Sci. 2024;31:223\u201333. https:\/\/doi.org\/10.1002\/jhbp.1391.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1596_CR34","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.7150\/ijms.25734","volume":"15","author":"A Shioya","year":"2018","unstructured":"Shioya A, Guo X, Motono N, Mizuguchi S, Kurose N, Nakada S, Aikawa A, Ikeda Y, Uramoto H, Yamada S. The combination of weak expression of PRDX4 and very high MIB-1 labelling index independently predicts shorter disease-free Survival in Stage I Lung Adenocarcinoma. Int J Med Sci. 2018;15:1025\u201334. https:\/\/doi.org\/10.7150\/ijms.25734.","journal-title":"Int J Med Sci"},{"key":"1596_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1089\/ars.2017.7426","volume":"30","author":"X Guo","year":"2019","unstructured":"Guo X, Noguchi H, Ishii N, Homma T, Hamada T, Hiraki T, Zhang J, Matsuo K, Yokoyama S, Ishibashi H, Fukushige T, Kanekura T, Fujii J, Uramoto H, Tanimoto A, Yamada S. The Association of Peroxiredoxin 4 with the Initiation and Progression of Hepatocellular Carcinoma. Antioxid Redox Signal. 2019;30:1271\u201384. https:\/\/doi.org\/10.1089\/ars.2017.7426.","journal-title":"Antioxid Redox Signal"},{"key":"1596_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.14670\/HH-18-666","volume":"38","author":"J Han","year":"2023","unstructured":"Han J, Itoh T, Shioya A, Sakurai M, Oyama T, Kumagai M, Takamura H, Okuro M, Mukai T, Kitakata H, Inagaki M, Higashi M, Guo X, Yamada S. The combination of the low immunohistochemical expression of peroxiredoxin 4 and perilipin 2 predicts longer survival in pancreatic ductal adenocarcinoma with peroxiredoxin 4 possibly playing a main role. Histol Histopathol. 2023;38:1415\u201327. https:\/\/doi.org\/10.14670\/HH-18-666.","journal-title":"Histol Histopathol"},{"key":"1596_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3969\/j.issn.1671-7414.2024.03.020","volume":"39","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Feng J. Study on the relationship among the expression of PRDX4 and GRAMD1A levels in Hepatocellular Carcinoma Tissues with clinicopathologic features and prognosis. J Mod Lab Med. 2024;39:120\u20134. https:\/\/doi.org\/10.3969\/j.issn.1671-7414.2024.03.020.","journal-title":"J Mod Lab Med"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01596-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01596-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01596-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T01:03:07Z","timestamp":1736298187000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-025-01596-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01596-4","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A statement on ethics approval and consent were written in the Methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the fnal version of the manuscript and have given their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}